A method of treating refractory or resistant pancreatic cancer by administering: (i) a cationic liposomal formulation comprising one or more cationic lipids and a therapeutically effective amount of paclitaxel; or (ii) a cationic liposomal formulation comprising one or more cationic lipids and a therapeutically effective amount of paclitaxel, and a therapeutically effective amount of gemcitabine.